NCT03439072 - G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 23, 2018

Primary Completion Date

April 18, 2018

Study Completion Date

May 3, 2018

Conditions

Insulin HypoglycemiaType 1 Diabetes MellitusSevere Hypoglycemia

Interventions

DRUG

G-Pen

1 mg subcutaneous injection of G-Pen (glucagon injection) administered via auto-injector

DRUG

Lilly Glucagon

1 mg subcutaneous injection of Lilly Glucagon (glucagon injection \[RNDA Origin\])

Trial Locations (6)

Atlanta Diabetes Associates, Atlanta

ProSciento, Inc., Chula Vista

Diablo Clinical Research, Inc., Walnut Creek

Rainier Clinical Research Center, Inc., Renton

LMC ESD, Inc., Toronto

Altasciences Algorithme Pharma, Montreal